Cullinan Therapeutics (CGEM) Change in Accured Expenses (2020 - 2023)
Historic Change in Accured Expenses for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to $5.1 million.
- Cullinan Therapeutics' Change in Accured Expenses rose 21977.26% to $5.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $10.1 million, marking a year-over-year increase of 1782.49%. This contributed to the annual value of $2.9 million for FY2024, which is 7120.55% down from last year.
- Cullinan Therapeutics' Change in Accured Expenses amounted to $5.1 million in Q4 2023, which was up 21977.26% from $5.2 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Change in Accured Expenses registered a high of $5.2 million during Q3 2023, and its lowest value of -$2.8 million during Q2 2023.
- Its 4-year average for Change in Accured Expenses is $1.6 million, with a median of $1.6 million in 2021.
- Over the last 5 years, Cullinan Therapeutics' Change in Accured Expenses had its largest YoY gain of 1330476.19% in 2021, and its largest YoY loss of 64511.63% in 2021.
- Quarter analysis of 4 years shows Cullinan Therapeutics' Change in Accured Expenses stood at -$21000.0 in 2020, then skyrocketed by 13304.76% to $2.8 million in 2021, then plummeted by 42.91% to $1.6 million in 2022, then skyrocketed by 219.77% to $5.1 million in 2023.
- Its Change in Accured Expenses stands at $5.1 million for Q4 2023, versus $5.2 million for Q3 2023 and -$2.8 million for Q2 2023.